



## Dosing Strategies for Protecting the Vulnerable

Guest Editors:

**Dr. Erwin Dreesen**

Department of Pharmaceutical  
and Pharmacological Sciences,  
University of Leuven, 3000  
Leuven, Belgium

**Dr. Pieter Van Brantegem**

Department of Bioengineering  
and Therapeutic Sciences,  
University of California, San  
Francisco, CA, USA

Deadline for manuscript  
submissions:  
**closed (20 February 2023)**

### Message from the Guest Editors

Dear Colleagues,

Many diseases have a disproportional impact on vulnerable patients, including but not limited to the very young and very old, obese patients, critically ill patients, and pregnant women. Paradoxically, their vulnerabilities are also the basis for excluding them from clinical trials. Many drugs are therefore not licensed for use in these patients but, rather, off-label use is often justified by the high unmet medical need. The selection of an appropriate dosing strategy for these patients is one of the main challenges.

Pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation can be used to characterise the relationship between drug dosing, drug exposure, biomeasures, biomarkers, and clinical outcomes. Furthermore, these models can be applied to identify optimised dosing strategies for vulnerable patients. Although the added value of using PK/PD models is being recognised in various disease areas, an extensive knowledge gap remains.

For this Special Issue, we welcome the submission of original research articles and reviews on modelling and simulation strategies for identifying dosing strategies to protect vulnerable patients.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

Pharmaceutics Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma